Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cystic Fibrosis

Progress in phase 2 clinical trial of cystic fibrosis drug candidate reported

Inspire has completed more than 50% of target enrollment in its ongoing phase 2 safety study, which is a double-blind, randomized comparison of 2 doses of denufosol tetrasodium (INS37217 Respiratory) to placebo in 72 patients with CF at 18 clinical centers across the United States.

This second phase 2 trial is being conducted in order to gain a greater understanding of safety and tolerability of denufosol in a broader population of CF patients, including patients with lower lung function and patients using antibiotics and other therapeutics,...

• View Other Issues of Medical Letter on the CDC & FDA
  
• View Other NewsRx Publications